Search research articles
Contact Us
Filters
Showing results (51-60 of 161) with videos related to
Page
of 17
Sort By:
Plos One
|
June 2, 2011
Targeting the DNA double strand break repair machinery in prostate cancer
Fadhel S Shaheen, Pawel Znojek, Ann Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules
Alan V Boddy, E Ruth Plummer, Radha Todd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2003
A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor
Ruth Plummer, Charlotte Rees, Andrew Hughes, et al.
British Journal of Cancer
|
February 21, 2019
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
Chris Twelves, Alan Anthoney, Claudio I Savulsky, et al.
Journal of Clinical Pharmacology
|
November 28, 2017
The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers
Karthick Vishwanathan, Paul A Dickinson, Khanh Bui, et al.
The Lancet. Oncology
|
February 11, 2021
SARS-CoV-2 vaccination and phase 1 cancer clinical trials
Timothy A Yap, Lillian L Siu, Emiliano Calvo, et al.
British Journal of Cancer
|
February 22, 2017
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
Richard H Wilson, Tr Jeffry Evans, Mark R Middleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2024
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
Timothy A Yap, Anthony W Tolcher, Ruth Plummer, et al.
Nature Communications
|
November 18, 2025
Multimodal AI and tumour microenvironment integration predicts metastasis in cutaneous melanoma
Tom W Andrew, Marc Combalia, Carlos Hernandez, et al.
Journal for Immunotherapy of Cancer
|
December 17, 2025
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1
Gary Middleton, Charlotte Gaskell, Joshua Savage, et al.
Page
of 17
Search research articles
Search
Showing results (51-60 of 161) with videos related to
Sort By:
Page
of 17
Plos One
|
June 2, 2011
Targeting the DNA double strand break repair machinery in prostate cancer
Fadhel S Shaheen, Pawel Znojek, Ann Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules
Alan V Boddy, E Ruth Plummer, Radha Todd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2003
A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor
Ruth Plummer, Charlotte Rees, Andrew Hughes, et al.
British Journal of Cancer
|
February 21, 2019
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
Chris Twelves, Alan Anthoney, Claudio I Savulsky, et al.
Journal of Clinical Pharmacology
|
November 28, 2017
The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers
Karthick Vishwanathan, Paul A Dickinson, Khanh Bui, et al.
The Lancet. Oncology
|
February 11, 2021
SARS-CoV-2 vaccination and phase 1 cancer clinical trials
Timothy A Yap, Lillian L Siu, Emiliano Calvo, et al.
British Journal of Cancer
|
February 22, 2017
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
Richard H Wilson, Tr Jeffry Evans, Mark R Middleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2024
First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
Timothy A Yap, Anthony W Tolcher, Ruth Plummer, et al.
Nature Communications
|
November 18, 2025
Multimodal AI and tumour microenvironment integration predicts metastasis in cutaneous melanoma
Tom W Andrew, Marc Combalia, Carlos Hernandez, et al.
Journal for Immunotherapy of Cancer
|
December 17, 2025
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1
Gary Middleton, Charlotte Gaskell, Joshua Savage, et al.
Page
of 17